Africa
The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
Amalia Adler-Waxman, vice president of Social Impact and Responsibility at Teva, told BioSpace that the company believes everyone should have access to essential medications, regardless of their geographic location.
The novel coronavirus that causes the disease COVID-19 continues to spread and has now been diagnosed in more than 50 countries.
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
A donation from leading temperature control packaging company Softbox Systems has enabled the charity International Health Partners to deliver cold-chain oncology medicines, giving children in Tanzania the chance to recover from cancer.
In the Congo, there have been more than 3,000 cases and 2,000 related deaths to the Ebola virus outbreak.
TB Alliance became the first nonprofit organization to win regulatory approval from the U.S. Food and Drug Administration for a new drug aimed at treating some of the most drug-resistant forms of tuberculosis.
Globally, TB is the leading cause of death by an infectious disease. It is caused by a bacterium, Mycobacterium tuberculosis.
PRESS RELEASES